0001562180-24-000338.txt : 20240108 0001562180-24-000338.hdr.sgml : 20240108 20240108170040 ACCESSION NUMBER: 0001562180-24-000338 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240104 FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Huang Jane CENTRAL INDEX KEY: 0001683913 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39527 FILM NUMBER: 24520905 MAIL ADDRESS: STREET 1: C/O MOURANT OZANNES CORPORATE SERVICES STREET 2: 94 SOLARIS AVENUE CITY: CAMANA BAY, GRAND CAYMAN STATE: E9 ZIP: KY1-1108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Prelude Therapeutics Inc CENTRAL INDEX KEY: 0001678660 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 811384762 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 175 INNOVATION BOULEVARD CITY: WILMINGTON STATE: DE ZIP: 19805 BUSINESS PHONE: (302) 467-1280 MAIL ADDRESS: STREET 1: 175 INNOVATION BOULEVARD CITY: WILMINGTON STATE: DE ZIP: 19805 FORMER COMPANY: FORMER CONFORMED NAME: Prelude Therapeutics Inc. DATE OF NAME CHANGE: 20160630 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-01-04 false 0001678660 Prelude Therapeutics Inc PRLD 0001683913 Huang Jane C/O PRELUDE THERAPEUTICS INCORPORATED 175 INNOVATION BOULEVARD WILMINGTON DE 19805 false true false false President, CMO false Common Stock 2024-01-04 4 M false 9375.00 A 49103.00 D Common Stock 2024-01-04 4 F false 3844.00 3.77 D 45259.00 D Restricted Stock Unit 2024-01-04 4 M false 9375.00 0.00 D Common Stock 9375.00 84375.00 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. /s/ Laurent Chardonnet, Attorney-in-Fact 2024-01-08